Participants currently enrolled in MARINA and MARINA-OLE™ trials may continue to be treated with AOC 1001
Avidity received Investigational New Drug (IND) clearance for FSHD and DMD studies from FDA; programs now advancing into the clinic
Company to host investor webcast today at 8:30 a.m. ET / 5:30 a.m. PT
Avidity's management team will host a webcast and conference call at 8:30 a.m. ET / 5:30 a.m. PT today, September 27, 2022. The live call can be accessed by dialing 866-652-5200 (US) and 412-317-6060 (International) and requesting Avidity Biosciences. A live webcast will also be available on the "Events and Presentations" page in the "Investors" section of Avidity's website. A replay of the webcast will be archived on Avidity's website following the event.
https://finance.yahoo.com/news/avidity-biosciences-announces-fda-partial-110000050.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.